Form 4: GUIDED THERAPEUTICS Director Boosts Stake with Conversions, Purchase

GUIDED THERAPEUTICS Director John E. Imhoff significantly increased his beneficial ownership through preferred stock conversions, dividend payments, and a direct purchase of common stock and warrants.

Summary

• John E. Imhoff, a Director and 10% owner of GUIDED THERAPEUTICS INC (GTHP), reported multiple transactions increasing his beneficial ownership.
• On August 21, 2025, Mr. Imhoff acquired 104,448 shares of common stock as payment for accrued dividends on his Series E preferred stock, at a conversion price of $0.2298 per share.
• Also on August 21, 2025, he converted 300 shares of Series E preferred stock, which had a stated value of $1,000 per share, into 1,200,000 shares of common stock at a conversion price of $0.25 per share.
• On August 29, 2025, Mr. Imhoff purchased 166,667 units from the company for a total price of $30,000. Each unit consisted of one share of common stock and one warrant.
• The common stock acquired in this purchase was at an effective price of approximately $0.18 per share.
• The warrants acquired on August 29, 2025, are immediately exercisable, have an exercise price of $0.25 per share, and expire on August 29, 2029.
• Following these transactions, Mr. Imhoff's direct beneficial ownership of common stock increased to 19,463,495 shares.
• His direct beneficial ownership of warrants increased to 191,667.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by a director and 10% owner, including a direct purchase, indicates strong insider confidence in the company's future prospects. However, the relatively low transaction prices for common stock and warrants suggest the company's current market valuation is modest.

Positives

• A Director and 10% owner, John E. Imhoff, significantly increased his beneficial ownership in the company, signaling strong insider confidence.
• The direct purchase of 166,667 units (common stock and warrants) for $30,000 demonstrates a personal investment at an effective price of $0.18 per common share.
• The conversion of Series E preferred stock into common stock simplifies the capital structure and increases the common stock float, potentially improving liquidity.

Negatives

• The effective purchase price of common stock at $0.18 and conversion price of $0.2298, along with a warrant exercise price of $0.25, suggests a relatively low current market valuation for the company's shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The company entered into a Securities Purchase Agreement with John E. Imhoff, a Director and 10% owner, for the sale of units consisting of common stock and warrants.

Stakeholder Impact

• Shareholders: May experience increased confidence due to significant insider buying, but also potential future dilution from warrant exercises.
• Company: Received $30,000 in capital from the unit sale, strengthening its financial position.

Key Dates

Recommendation

The significant increase in beneficial ownership by a director and 10% owner, including a direct purchase of common stock and warrants, signals strong insider confidence. This suggests management believes the stock is undervalued and has significant upside potential, making it an attractive opportunity for investors.

Keywords

GUIDED THERAPEUTICS, GTHP, insider trading, Form 4, beneficial ownership, common stock, preferred stock, warrants, director, 10% owner, stock conversion, stock purchase